Printer Friendly

IMMUNOMEDICS WINS U.S. PATENT OFFICE APPEAL; BROAD U.S. PATENT ON ORGAN IMAGING ALLOWED

              IMMUNOMEDICS WINS U.S. PATENT OFFICE APPEAL;
               BROAD U.S. PATENT ON ORGAN IMAGING ALLOWED
    WARREN, N.J., Nov. 13 /PRNewswire/ -- Immunomedics, Inc. (NASDAQ: IMMU) today announced that the U.S. Patent and Trademark Office ruled, in a final appeal, to allow the issuance to Immunomedics of patent claims originally filed in 1985.
    The patent claims cover the use of radioisotopes or magnetic resonance contrast agents attached to monoclonal antibodies or antibody fragments that bind selectively to normal body organs and tissues. These new reagents enable images to be made of normal organs of the body by nuclear medicine or magnetic resonance imaging devices, whereby disease areas show up as defects or "cold spots."
    Dr. David M. Goldenberg, the inventor of this new technology, commented, "These claims have very broad and general application to improved radiological diagnosis.  For example, a bone marrow-targeting antibody can be given to reveal cancer in this tissue, particularly metastasis, or spread, from cancers of the breast or prostate."
    Russell C. McLauchlan, president of Immunomedics, said, "This new patent, which will bring the total issued to Immunomedics in the U.S. to 22 and 67 in foreign countries, provides a new class of imaging agents which should improve early and more accurate diagnosis of various diseases, including cancer and infections.  We are already in clinical trials with a granulocyte imaging agent which may also permit the visualization of cancer spread to the bone marrow.  "This should enable physicians to better stage the extent of cancer in patients," he added.
    Immunomedics is a biopharmaceutical company applying innovative technology in antibody selection, modification and chemistry to the development of products for the detection and treatment of cancers and infectious diseases.  Integral to these products are highly specific monoclonal antibodies designed to deliver radioisotopes, chemotherapeutic agents or toxins to tumors and sites of infections or other diseases.
    -0-        11/13/91
    /CONTACT:  Amy Factor of Immunomedics, 908-647-5400/
    (IMMU) CO:  Immunomedics, Inc. ST:  New Jersey IN:  MTC SU: CK-OS -- NY016 -- 3838 11/13/91 10:12 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 13, 1991
Words:337
Previous Article:THE ARES-SERONO GROUP REPORTS THIRD QUARTER AND NINE MONTHS SALES AND EARNINGS
Next Article:ATLAS REPORTS FIRST QUARTER RESULTS
Topics:


Related Articles
IMMUNOMEDICS AWARDED PATENT FOR IMAGING AND THERAPEUTIC AGENTS
IMMUNOMEDICS ALLOWED PATENT FOR NEW CANCER IMAGING & THERAPY METHODS & AGENTS: FEDERAL GRANT FOR CANCER THERAPEUTIC ALSO AWARDED
IMMUNOMEDICS RECEIVES BROAD EUROPEAN PATENT FOR HIGHLY SPECIFIC CANCER TARGETING ANTIBODIES
IMMUNOMEDICS GRANTED THREE PATENTS IN JAPAN
Immunomedics Awarded U.S. Patent for Therapeutic Conjugates of Toxins and Drugs
Immunomedics Wins Patent in Japan
Immunomedics patents new '2-Punch' therapy of cancer with bispecific fusion proteins.
Immunomedics obtains patent for therapy of B-cell malignancies using antibodies.
Immunomedics obtains lymphoma antibody patent.
Immunomedics granted additional patent.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters